<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="New York UniversityUnited States *Email: tjl229@nyu.edu. epub: 2020-06-06collection: 2020-07-07pmc-release: 2020-06-0611713571360(C)" exact="American" post="Chemical Society, 2020This article is made available via the"/>
 <result pre="provides an overview of important molecular pathways involved in the" exact="viral" post="life cycle of SARS-CoV-2, the infectious agent of COVID-19."/>
 <result pre="pathways involved in the viral life cycle of SARS-CoV-2, the" exact="infectious" post="agent of COVID-19. We highlight past and recent findings"/>
 <result pre="inhibitors of SARS-CoV-2 infection. By discussing the current inventory of" exact="viral" post="inhibitors, we identify molecular scaffolds that may be improved"/>
 <result pre="antivirals Most of the worldâ€™s initial efforts to treat Coronavirus" exact="Disease" post="2019 (COVID-19) have focused on the repurposing of approved"/>
 <result pre="as we seek quick solutions to a pandemic, caused by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The recent announcement"/>
 <result pre="we seek quick solutions to a pandemic, caused by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The recent announcement of"/>
 <result pre="seek quick solutions to a pandemic, caused by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). The recent announcement of the"/>
 <result pre="quick solutions to a pandemic, caused by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). The recent announcement of the antiviral"/>
 <result pre="Fauci, the director of the National Institute of Allergy and" exact="Infectious" post="Disease (NIAID) said that the completed clinical trial with"/>
 <result pre="the director of the National Institute of Allergy and Infectious" exact="Disease" post="(NIAID) said that the completed clinical trial with remdesivir"/>
 <result pre="against SARS-CoV infections. Related coronaviruses, SARS-CoV-1 and MERS-CoV (Middle East" exact="Respiratory" post="Syndrome Coronavirus), caused serious, albeit less widespread, health epidemics"/>
 <result pre="SARS-CoV infections. Related coronaviruses, SARS-CoV-1 and MERS-CoV (Middle East Respiratory" exact="Syndrome" post="Coronavirus), caused serious, albeit less widespread, health epidemics starting"/>
 <result pre="reviews and essays have outlined vaccine efforts, as well as" exact="viral" post="and host targets that are the focus of current"/>
 <result pre="at redirecting clinically used compounds for COVID-19.1 Here, we outline" exact="viral" post="pathways that contain druggable targets currently overlooked and propose"/>
 <result pre="general mechanisms to disrupt these pathways. We begin with a" exact="short" post="primer on the SARS-CoV-2 viral life cycle and an"/>
 <result pre="pathways. We begin with a short primer on the SARS-CoV-2" exact="viral" post="life cycle and an overview of existing drugs that"/>
 <result pre="We then focus on alternative druggable targets largely within the" exact="viral" post="replicase machinery, as well as viral entry and proteolytic"/>
 <result pre="targets largely within the viral replicase machinery, as well as" exact="viral" post="entry and proteolytic processing pathways. Our proposed strategies for"/>
 <result pre="to specifically disarm coronaviruses in the host. Overview of the" exact="Viral" post="Life Cycle The genome organization of SARS-CoV-2 is similar"/>
 <result pre="the Î²-coronavirus family that also include SARS-CoV-1 and MERS-CoV.2 The" exact="viral" post="RNA-encoded proteins can be divided into two main classes:"/>
 <result pre="proteins (spike, envelope, membrane, nucleocapsid, and hemagglutinin esterase) form the" exact="viral" post="particle and play additional functional roles during infection. Viral"/>
 <result pre="the viral particle and play additional functional roles during infection." exact="Viral" post="infection begins with an interaction between the viral spike"/>
 <result pre="viral particle and play additional functional roles during infection. Viral" exact="infection" post="begins with an interaction between the viral spike glycoprotein"/>
 <result pre="during infection. Viral infection begins with an interaction between the" exact="viral" post="spike glycoprotein (S protein) and a receptor, angiotensin-converting enzyme"/>
 <result pre="known to prime the trimer of S protein on the" exact="viral" post="particle surface prior to cell entry. Cleavage of S"/>
 <result pre="protein into two subunits is required for the process of" exact="viral" post="and host membrane fusion prior to viral uptake by"/>
 <result pre="the process of viral and host membrane fusion prior to" exact="viral" post="uptake by an endocytic mechanism. Figure 1 Overview of"/>
 <result pre="by an endocytic mechanism. Figure 1 Overview of the proposed" exact="viral" post="life cycle of SARS-CoV-2, the infectious agent of COVID-19."/>
 <result pre="Overview of the proposed viral life cycle of SARS-CoV-2, the" exact="infectious" post="agent of COVID-19. Both viral and host machinery are"/>
 <result pre="life cycle of SARS-CoV-2, the infectious agent of COVID-19. Both" exact="viral" post="and host machinery are essential for viral infection, replication,"/>
 <result pre="of COVID-19. Both viral and host machinery are essential for" exact="viral infection," post="replication, reassembly, and egress. Remdesivir, the only FDA approved"/>
 <result pre="for COVID-19 treatment, blocks RNA replication. Highlighted are points of" exact="viral" post="interference that have not been widely exploited: (1) inhibition"/>
 <result pre="been widely exploited: (1) inhibition of additional components of the" exact="viral" post="replicationâ€&quot;transcription complex (RTC); (2) development of new modes of"/>
 <result pre="replicationâ€&quot;transcription complex (RTC); (2) development of new modes of disrupting" exact="viral" post="protease activities; and (3) exploration of peptide-based inhibitors to"/>
 <result pre="membrane fusion. Following engulfment and subsequent release from the endosome," exact="viral" post="genetic material is released into the host cytoplasm prior"/>
 <result pre="the host cytoplasm prior to translation of the single stranded" exact="viral" post="RNA into long polypeptides that contain the nsps. Viral"/>
 <result pre="stranded viral RNA into long polypeptides that contain the nsps." exact="Viral" post="polypeptides are predicted to be cleaved into 16 individual"/>
 <result pre="accessory proteins. Following multiple cycles of replication and translation, the" exact="viral" post="particle assembles and exits the cell though a budding"/>
 <result pre="replicate. Known Drugs in Clinical Trials for COVID-19 Target the" exact="Viral" post="Life Cycle The World Health Organization (WHO) and federal"/>
 <result pre="drugs that are proposed to target some aspect of the" exact="viral" post="life cycle described above (Figure 1). The NIH now"/>
 <result pre="remdesivir, is a nucleotide analog originally developed to treat Ebola" exact="infections" post="(caused by another single-stranded RNA virus) and recently shown"/>
 <result pre="hydroxychloroquine and chloroquine, both of which are approved to treat" exact="malaria" post="and various autoimmune disorders, and might function by disrupting"/>
 <result pre="both of which are approved to treat malaria and various" exact="autoimmune" post="disorders, and might function by disrupting endosome-mediated entry or"/>
 <result pre="on COVID-19 progression or plan to test antibodies raised against" exact="viral" post="proteins.1 Viral RNA Replicase Machinery Contains Alternative Viable Targets"/>
 <result pre="progression or plan to test antibodies raised against viral proteins.1" exact="Viral" post="RNA Replicase Machinery Contains Alternative Viable Targets The success"/>
 <result pre="remdesivir in clinical trials, although limited, suggests that inhibition of" exact="viral" post="replication is a viable strategy for the treatment of"/>
 <result pre="it takes more than a single polymerase to replicate the" exact="viral" post="genome and ensure pathogenicity. SARS-CoV-2 is thought to involve"/>
 <result pre="proteins are not targets in current COVID-19 clinical trials. The" exact="viral" post="RTC proteins are expressed in the cytoplasm and so"/>
 <result pre="are motor proteins necessary for unwinding double-stranded RNA, which form" exact="secondary" post="structures, in order for replication and translation to occur."/>
 <result pre="structures, in order for replication and translation to occur. Since" exact="viral" post="helicases typically share low homology with human DNA helicases,"/>
 <result pre="to the helicase core domain were shown to cause a" exact="deficiency" post="in nucleic acid unwinding.9 As a result, there are"/>
 <result pre="second polymerase (nsp8) is hypothesized to be a primase.2 The" exact="primary" post="sequences of nsp7, 8 and RdRP are â‰¥96% identical"/>
 <result pre="the past and has been reviewed in detail elsewhere.8 Importantly," exact="herpes" post="simplex virus (HSV) helicase UL5 is a member of"/>
 <result pre="1), exhibit nanomolar antiviral activity and are selective for HSV" exact="infection" post="in mouse models. The clinically used amenamevir (2), another"/>
 <result pre="infection in mouse models. The clinically used amenamevir (2), another" exact="herpes" post="antiviral, also targets in the helicaseâ€&quot;primase at nanomolar concentrations.8"/>
 <result pre="SSYA10-001 (3), which shows micromolar activity against SARS-CoV-1 and MERS-CoV" exact="infections" post="in vitro, was awarded a US patent in 2014.13,14"/>
 <result pre="of coronavirus helicase modulators. Figure 2 Select chemical scaffolds for" exact="viral" post="target disruption. Existing viral helicase inhibitors (1â€&quot;3),8,11,14 including the"/>
 <result pre="Figure 2 Select chemical scaffolds for viral target disruption. Existing" exact="viral" post="helicase inhibitors (1â€&quot;3),8,11,14 including the SARS-CoV-1 helicase binder SSYA10-001"/>
 <result pre="inhibitors (1â€&quot;3),8,11,14 including the SARS-CoV-1 helicase binder SSYA10-001 (2) and" exact="viral" post="protease inhibitors (4â€&quot;5).15,17 Novel Strategies for Targeting Viral Proteases"/>
 <result pre="(2) and viral protease inhibitors (4â€&quot;5).15,17 Novel Strategies for Targeting" exact="Viral" post="Proteases Although many host proteases are deemed essential for"/>
 <result pre="are deemed essential for late-stage processing of proteins translated from" exact="viral" post="RNA, viral 3CLpro (also called Mpro) and PLP have"/>
 <result pre="essential for late-stage processing of proteins translated from viral RNA," exact="viral" post="3CLpro (also called Mpro) and PLP have emerged as"/>
 <result pre="are predicted to belong to this class, design of specific" exact="viral" post="inhibitors remains a challenge. Fortunately, to aid in the"/>
 <result pre="with other inhibitors that have been reviewed elsewhere.16 Another viable" exact="viral" post="target, PLP, shows lower sequence conservation between SARS-CoV-1 and"/>
 <result pre="have been reviewed elsewhere.16 Another viable viral target, PLP, shows" exact="lower" post="sequence conservation between SARS-CoV-1 and CoV-2 (76% homology). Notably,"/>
 <result pre="of the ubiquitin-like modifier, ISG15. These PLP-dependent activities contribute to" exact="viral" post="immune evasion in the host. Inhibitors of PLP-mediated ISG15"/>
 <result pre="compound 5, have EC50 values of âˆ¼10 uM against SARS-CoV-1" exact="infection" post="in cell culture with no associated cytotoxicity.17 Structural information"/>
 <result pre="against SARS-CoV-1 infection in cell culture with no associated cytotoxicity.17" exact="Structural" post="information and the noted unique features of SARS-CoV cysteine"/>
 <result pre="inhibition, but existing scaffolds still require optimization to disable SARS-CoV-2" exact="infections" post="in the host. Peptide-Based Approaches for Membrane Fusion Inhibitors"/>
 <result pre="form a six-helical bundle, and in so doing bring the" exact="viral" post="and host membrane proximal to one another resulting in"/>
 <result pre="another resulting in fusion. This fusion process is essential for" exact="viral" post="entry. Design of â€œcoiled coilâ€� heptad repeat-based peptides provides"/>
 <result pre="lipidated peptide fusion inhibitors have been designed that inhibit pseudovirus" exact="infection" post="of cells with IC50 values in the single-digit nanomolar"/>
 <result pre="initial literature research. Abbreviations ACE2 angiotensin-converting enzyme 2 COVID-19 Coronavirus" exact="Disease" post="2019 SARS-CoV Severe Acute Respiratory Syndrome Coronavirus S protein"/>
 <result pre="Abbreviations ACE2 angiotensin-converting enzyme 2 COVID-19 Coronavirus Disease 2019 SARS-CoV" exact="Severe" post="Acute Respiratory Syndrome Coronavirus S protein spike glycoprotein nsp(s)"/>
 <result pre="ACE2 angiotensin-converting enzyme 2 COVID-19 Coronavirus Disease 2019 SARS-CoV Severe" exact="Acute" post="Respiratory Syndrome Coronavirus S protein spike glycoprotein nsp(s) nonstructural"/>
 <result pre="angiotensin-converting enzyme 2 COVID-19 Coronavirus Disease 2019 SARS-CoV Severe Acute" exact="Respiratory" post="Syndrome Coronavirus S protein spike glycoprotein nsp(s) nonstructural protein(s)"/>
 <result pre="enzyme 2 COVID-19 Coronavirus Disease 2019 SARS-CoV Severe Acute Respiratory" exact="Syndrome" post="Coronavirus S protein spike glycoprotein nsp(s) nonstructural protein(s) RTC"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting Wuhan. Emerging Microbes Infect.2020, 9, 221â€&quot;236. 10.1080/22221751.2020.1719902."/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting Wuhan. Emerging Microbes Infect.2020, 9, 221â€&quot;236. 10.1080/22221751.2020.1719902."/>
 <result pre="GuoJ.; ZhengL.; MingZ.; ZhangL.; LouZ.; RaoZ.Delicate structural coordination of the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus nsp13 upon ATP hydrolysis. Nucleic"/>
 <result pre="ZhengL.; MingZ.; ZhangL.; LouZ.; RaoZ.Delicate structural coordination of the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus nsp13 upon ATP hydrolysis. Nucleic Acids"/>
 <result pre="MingZ.; ZhangL.; LouZ.; RaoZ.Delicate structural coordination of the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus nsp13 upon ATP hydrolysis. Nucleic Acids Res.2019,"/>
 <result pre="ZhangL.; LouZ.; RaoZ.Delicate structural coordination of the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus nsp13 upon ATP hydrolysis. Nucleic Acids Res.2019, 47"/>
 <result pre="RÃ¼bsamen-WaigmannH.New helicase-primase inhibitors as drug candidates for the treatment of" exact="herpes" post="simplex disease. Nat. Med.2002, 8 (4), 392â€&quot;8. 10.1038/nm0402-392.11927946 AdedejiA."/>
 <result pre="SarafianosS. G.Evaluation of SSYA10â€&quot;001 as a replication inhibitor of severe" exact="acute" post="respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome"/>
 <result pre="G.Evaluation of SSYA10â€&quot;001 as a replication inhibitor of severe acute" exact="respiratory" post="syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses."/>
 <result pre="of severe acute respiratory syndrome, mouse hepatitis, and Middle East" exact="respiratory" post="syndrome coronaviruses. Antimicrob. Agents Chemother.2014, 58 (8), 4894â€&quot;8. 10.1128/AAC.02994-14.24841268"/>
 <result pre="severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory" exact="syndrome" post="coronaviruses. Antimicrob. Agents Chemother.2014, 58 (8), 4894â€&quot;8. 10.1128/AAC.02994-14.24841268 SarafianosG."/>
 <result pre="A.; SinghK.Suppression of Sars Replication by Sars Helicase Inhibitors. US" exact="Patent" post="WO 20140005241, January 2, 2014. ZhangL.; LinD.; SunX.; CurthU.;"/>
 <result pre="10.1126/science.abb3405.32198291 PillaiyarT.; ManickamM.; NamasivayamV.; HayashiY.; JungS. H.An overview of severe" exact="acute" post="respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small"/>
 <result pre="PillaiyarT.; ManickamM.; NamasivayamV.; HayashiY.; JungS. H.An overview of severe acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule"/>
 <result pre="QinC.; SunF.; ShiZ.; ZhuY.; JiangS.; LuL.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
</results>
